biologics Archives

First Opinion William S. Smith

The Biden administration needs to look beyond ICER for evaluating drug therapies

Pharmalot Ed Silverman

Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?

Biotech Elizabeth Cooney

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

First Opinion Sean McGowan

Five years on, biosimilars need support from all health care players

Politics Erin Mershon

Drug makers jostle over potential Medicare changes in congressional spending deal

First Opinion Michelle Hoffmann

Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?

Business Associated Press

Samsung’s biotech unit debuts in Seoul. Here’s what to know

In the Lab Eric Boodman

Freeze-dried drug factories could make a slew of medicines — just add water

Pharmalot Ed Silverman

Biosimilar names may affect pharmacist dispensing habits

Pharmalot Ed Silverman

Some biosimilars are just as good as some pricey biologics

Pharmalot Ed Silverman

Teva, one of the biggest generic makers, joins the brand-name club

Pharmalot Ed Silverman

Court ruling on biosimilar launches could increase health care costs

Pharmalot Ed Silverman

Bill introduced to speed cheaper versions of pricey biologics to market

Pharmalot Ed Silverman

Supreme Court asks Obama administration for views on biosimilar rules

Pharmalot Ed Silverman

Unintended twist in Obamacare may cost some Medicare patients more for biosimilars

Pharmalot Ed Silverman

biologics

Most Read

From bench to bedside, biologics require excellence at every stage

Biologics lose protection as U.S.-Canada-Mexico trade agreement moves forward

Lawmakers slip a win for pharma into federal spending package

Facing bottlenecks in manufacturing cell therapies, Boston leaders plan to build their own

Trade agreement drug monopoly is obsolete given faster, better drug discovery

U.S. biologics and biosimilars need distinguishable names

Biosimilar approval and adoption in the U.S. needs to be expedited

Microbiome-based drugs likely to face FDA’s biologics pathway

All Coverage

The Biden administration needs to look beyond ICER for evaluating drug therapies

Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

Five years on, biosimilars need support from all health care players

Drug makers jostle over potential Medicare changes in congressional spending deal

Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?

Samsung’s biotech unit debuts in Seoul. Here’s what to know

Freeze-dried drug factories could make a slew of medicines — just add water

Biosimilar names may affect pharmacist dispensing habits

Some biosimilars are just as good as some pricey biologics

Teva, one of the biggest generic makers, joins the brand-name club

Court ruling on biosimilar launches could increase health care costs

Bill introduced to speed cheaper versions of pricey biologics to market

Supreme Court asks Obama administration for views on biosimilar rules

Unintended twist in Obamacare may cost some Medicare patients more for biosimilars

FDA proposes biosimilar labeling that favors generic drug makers

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day